HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
Representing an investment of more than 50 million euros, this new unit dedicated to the bioproduction of pharmaceutical-grade hyaluronic acid represents a pivotal stage in the development of HTL and the largest investment ever made in the world for a biopolymer production unit.
It will enable HTL to become the largest producer of pharmaceutical-grade hyaluronic acid in the world and accelerate its international development.
Read more below.
We’re pleased to share our second CSR report, highlighting the actions and commitments we carried out throughout 2024.
A Global Scientific Gathering Dedicated to Hyaluronic Acid Innovation.
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.